Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives Average Rating of "Buy" from Brokerages

Key Points

• Analyst sentiment is broadly positive: Twelve analysts give Maze Therapeutics an average “Buy” rating, including eight buys and three strong buys, with an average 12-month price target of $66.
• Insiders have been selling shares: Executives sold approximately 209,612 shares worth $5.7 million over the past three months, though the transactions were conducted under pre-arranged Rule 10b5-1 plans.
• The stock faces financial and technical challenges: MAZE opened at $26.21, below its 50-day and 200-day moving averages, while the company remains loss-making and analysts expect a full-year loss of roughly $2.72 per share.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) has received an average recommendation of "Buy" from the twelve analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, eight have issued a buy rating and three have given a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $66.00.

A number of research analysts have issued reports on MAZE shares. Wall Street Zen lowered shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. BTIG Research reissued a "buy" rating and issued a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday, August 12th. TD Cowen upgraded Maze Therapeutics to a "strong-buy" rating in a research note on Monday, August 24th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th.

Insider Transactions at Maze Therapeutics

In related news, CEO Jason Coloma sold 34,501 shares of Maze Therapeutics stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $26.29, for a total transaction of $907,031.29. Following the completion of the sale, the chief executive officer owned 18,151 shares of the company's stock, valued at $477,189.79. The trade was a 65.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,142 shares of the company's stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $27.61, for a total value of $445,680.62. Following the completion of the sale, the chief marketing officer owned 16,142 shares in the company, valued at approximately $445,680.62. This represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 209,612 shares of company stock worth $5,734,575 over the last three months. 5.30% of the stock is currently owned by insiders.

Institutional Trading of Maze Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in MAZE. Royal Bank of Canada grew its holdings in Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company's stock worth $27,000 after acquiring an additional 363 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Maze Therapeutics during the 4th quarter worth approximately $43,000. California State Teachers Retirement System increased its holdings in shares of Maze Therapeutics by 138.0% during the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company's stock valued at $55,000 after purchasing an additional 766 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Maze Therapeutics during the 2nd quarter valued at approximately $48,000. Finally, Ameritas Investment Partners Inc. lifted its stake in shares of Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock valued at $42,000 after purchasing an additional 738 shares during the period.

Maze Therapeutics Trading Up 1.3%

Maze Therapeutics stock opened at $26.21 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The stock has a market cap of $1.46 billion, a PE ratio of -10.40 and a beta of 2.17. The stock has a 50-day moving average of $28.69 and a two-hundred day moving average of $31.17. Maze Therapeutics has a one year low of $14.27 and a one year high of $53.65.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.76). On average, research analysts anticipate that Maze Therapeutics will post -2.72 EPS for the current fiscal year.

Key Headlines Impacting Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

About Maze Therapeutics

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source